Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine for Anorexia-Cachexia Syndrome in Cancer Patients Receiving Neoadjuvant Chemotherapy
NCT07633236Phase 3Recruiting
- Sponsor
- N.N. Blokhin Russian Cancer Research Center
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
A Phase 3 trial of olanzapine in anorexia-cachexia syndrome (ACS), sponsored by N.N. Blokhin Russian Cancer Research Center. Started Mar 2025; status: recruiting.
02
Drugs
olanzapine
03
Conditions
anorexia-cachexia syndrome (ACS)
Beyond the preview
Go deeper on NCT07633236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07633236.